signal

research

Anavex Life Sciences Corporation

wait

Seems crazy to me to unjust approvals that are going on while we wait on legitimate results!!!

But why wait 3 years with that when Anavex 50mg dose is likely better! !

So, if one waits months for an answer and then has to resubmit to another journal it can hold things up.

This is a shitshow till data is presented.

loss

but  losses  and  disappointment  with  Missling.

$AVXL Took my $250 loss and Got out guys too much noise not enough action.

but was faked by the move and held them to expiration and had to book a loss of $19,000.

shareholder

The krout has proven to be an a hole toward shareholders.

Missling is a greedy pig, doesnt see the bad he does by delaying intentionally, not only to shareholders,

i am telling for years that we need to fire that shitty guy just here to full his pockets without any consideration for his shareholders.

.this guy doesnt respect his shareholders and he must be sue for that.

$AVXL fire Missling, he has been here 9 years and done nothing to drive shareholder value other than BS hype

$AVXL why does the company not believe they are beholden to their shareholders?

$AVXL Unfortunately the Investorshub AVXL board has deteriorated to the point that it is basically a board consisting of almost entirely FUD with almost more bashers than true shareholders.

Messling is grossly deficient in anticipating the expectations of shareholders and the market.

$AVXL as corporate shareholder, I have sent an email on dec. 21st and a friendly reminder yesterday to IR - no response yet !!

One hand he says he care for shareholder value, on other hand he is purposely not sharing updates.

shareprice

$AVXL missling next time should change a few letters when hiring and SP will improve: from FDA to FBI former employee.

$AVXL Every time Missling speaks, the SP tanks…..amateurish communication, unbelievable.

It&#39;s stupid, it wastes time (and $$$) and it leaves the company vulnerable with a supressed SP.

Based on Rett alone, SP is well under 100$, sorry to bust your ballown,but please try to stay realist and keep a little credibility!

$AVXL The sp is wrong there must be a glitch

$AVXL not that i am happy with the SP overall

$AVXL Until you realize that and admit that the presenter screwed up in rushing the presentation the SP will stay where it’s at

$AVXL wandering when we will cross ANVS SP ;) 
never again!!!!

$AVXL we didnt cross ANVS SP yet, no good haha!

show

Take your money from this shit show and deposit in your bank account.

What an absolute unregulated criminal shit show this market has become.

Missling shows poor judgement and is not suited to be ceo.

SHOWS THE EXTREME WEAKNESS AND  DISTRESS THE STOCK IS UNDER.

but need more time to evaluate and announce a conference call for Monday instead we have a shit show.

The signal given in both the small phase 2a and the phase 2 double blinded placebo controlled PDD trial is what leads me to believe data will be good to great.

I made good profits on Friday and have left profits in stock in support of the research.

Also like the fact that the drug intervenes in tau blocking as that is also a target in AD research.

Research would show there is a significant chance of awesome results here,

Brilliant because the government in Australia recognizes the value of research and grants 43.5% return on each dollar spent.

business-result

Anavex&#39;s A2-73 Blarcamesine&#39;s trial results on 2 previously completed adult phase-3 trials were highly successful.

But the company actually has never seen before wonderful results.

If results hold up, the stock will achieve massive gains.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

Alzheimer&#39;s is the most valuable and most difficult indication and most desired lately..  and only Anavex really has some great results with a great safety record. .

The  sava  results  trounce  you  guys  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

Sava has potential and the phase 3 results will show the truth.

drug

- Timo grimmer is in the team 
- All endpoints of the clinical trial were reached 
 
I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

we have a drug, even many drugs, good for so many indications,  to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

I&#39;m looking forward to seeing the long term AD data on ANVS and have the feeling it&#39;s going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

trial

$AVXL amazing  avxl  still  in  singke  digits  after  a  supposedly  amazing  “pivotal”  trial  readout  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA  eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

Lam Research Corp.

rating

shit

Need to short this crap lollllllll!!!!!!!! Brrrrrr!!!

Fuck, AMD has to find someone red to sell off with

Has to bounce a bit before going to shit. No?

We alerted the SELL signal at $515.18 and we were able to close this one with profit at $508.08 🎯

We alerted the BUY signal at $485.18 and we were able to close this one with profit at $494.49 😎

We alerted the BUY signal at $488.96 and we were able to close this one with profit at $491.65 🥳

$LRCX Bullish technical pattern building based on 7 signals.

$LRCX Bullish technical pattern building based on 4 signals.

$LRCX Bullish technical pattern building based on 10 signals.

Lam Research upgraded by KGI Securities to outperform.

$LRCX (+1.8% pre) Lam Research Posts Strong Earnings.

Shares of Lam Research are down 56% year-to-date and are cheaper than ever.

earnings

$LRCX $EPD $UPS  CRWD CrowdStrike Holdings Options Ahead Of Earnings 
 
📈FREE trade-of-week via(Google Search) ⟶  𝐟𝐫𝐞𝐞𝐚𝐥𝐞𝐫𝐭.𝐩𝐰

so good huh😅..Anyway, cubie dont feel like shorting nice earnings especially wen dia stock has sold off so much in just last month.

$LRCX - earnings and guidance are great…buy the dip…near term 400…imo

$LRCX without the China headwind we would be over 600 now with such stellar earnings

china

Think it will still do well, even w/  up to $2.5 bln revenue hit from U.S. curbs on China exports

buying

$LRCX time to start seriously thinking of buying this.

ACM Research Inc - Ordinary Shares - Class A

We alerted the BUY signal at $10.81 and we were able to close this one with profit at $11.85 🔏

$ACMR Bullish technical pattern building based on 9 signals.

$ACMR  
ACM Research (NASDAQ:ACMR) shareholder returns have been stellar, earning 138% in 5 years

Their third quarter preliminary revenue releases in a week and based on research, should lead to a large yield.

indicator

$ACMR in Uptrend: price expected to rise as it breaks its lower Bollinger Band on December 22, 2022.

$ACMR All indicators still bullish, holding out against short attacks.

share

📈 Scan as of now “SWING TRADE SCANNER (2)” 01/03/2023 
 
$AUPH #1 on the scanner with 15.4 million shares traded and up by 38.43%, $ACMR #2 with 2.7 million shares traded and up by 26.33% 
 
Good luck everyone 🍀

Those 5  million short  shares are  going to offer some serious support  going forward.

Top Stocks matching your search for "signal research"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Dec, 2, 2022

Nov, 22, 2022

LRCX

Lam Research Corp.

-4.85%

$533.24 - $507.36

Mar, 18, 2023

Mar, 15, 2023

ACMR

ACM Research Inc - Ordinary Shares - Class A

-3.88%

$12.36 - $11.88

Mar, 7, 2023

Nov, 15, 2022

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Dec, 2, 2022

Nov, 22, 2022

LRCX

Lam Research Corp.

-4.85%

$533.24 - $507.36

Mar, 18, 2023

Mar, 15, 2023

Mar, 5, 2023

Nov, 17, 2022

Nov, 1, 2022

Oct, 5, 2022

ACMR

ACM Research Inc - Ordinary Shares - Class A

-3.88%

$12.36 - $11.88